Bigotti G, Coli A
Istituto di Anatomia Patologica, Università Cattolica del Sacro Cuore, Roma, Italy.
Tumori. 1990 Aug 31;76(4):374-8. doi: 10.1177/030089169007600414.
To investigate the relationship of morphologic appearance with other parameters such as age at diagnosis, primary site and clinical stage in regard to the prognosis, we examined a total of 20 neuroblastomas of various sites from children undergoing treatment at the Catholic University of Rome and Regina Elena Cancer Institute of Rome. We used a histopathologic classification, developed by Shimada et al. (JNCI, 1984), based on the presence of Schwann cells and ganglio-neuromatous component, neuroblastic maturation and transition to ganglionic forms, and number of mitotic and karyorrhetic nuclei. We observed a 100% 2-year survival for patients in the favorable groups (13 patients) and 0% 2-year survival for children (7 patients) in the group with unfavorable histology. Furthermore, immunohistochemical evaluation of neural markers such as NSE, S-100 protein and neurofilaments offered additional important information. Our results confirm that the combination of pathologic, immunohistochemical and clinical criteria can be usefully employed to predict the outcome of neuroblastomas.
为了研究形态学表现与其他参数(如诊断时的年龄、原发部位和临床分期)在预后方面的关系,我们检查了罗马天主教大学和罗马雷吉娜·埃琳娜癌症研究所正在接受治疗的儿童的总共20例不同部位的神经母细胞瘤。我们采用了岛田等人(《美国国家癌症研究所杂志》,1984年)开发的一种组织病理学分类方法,该方法基于施万细胞和神经节神经瘤成分的存在、神经母细胞成熟和向神经节形式的转变,以及有丝分裂和核溶解核的数量。我们观察到,组织学良好组的患者(13例)2年生存率为100%,组织学不良组的儿童(7例)2年生存率为0%。此外,对神经标志物如神经元特异性烯醇化酶(NSE)、S-100蛋白和神经丝的免疫组织化学评估提供了额外的重要信息。我们的结果证实,病理、免疫组织化学和临床标准的结合可有效地用于预测神经母细胞瘤的预后。